Edition:
United Kingdom

Shilpa Medicare Ltd (SHME.NS)

SHME.NS on National Stock Exchange of India

630.00INR
8:55am GMT
Change (% chg)

Rs-0.65 (-0.10%)
Prev Close
Rs630.65
Open
Rs634.40
Day's High
Rs634.75
Day's Low
Rs622.30
Volume
7,487
Avg. Vol
35,963
52-wk High
Rs786.90
52-wk Low
Rs535.10

Latest Key Developments (Source: Significant Developments)

Shilpa Medicare Gets 483 Observations From U.S. FDA For SEZ Formulation Facilities In Telangana
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Shilpa Medicare Ltd ::SAYS GOT 483 OBSERVATIONS FROM U.S. FDA IN RELATION TO SEZ FORMULATION FACILITIES SITUATED AT JADCHERLA, TELANGANA.SAYS TOTAL 10 OBSERVATIONS WERE CITED DURING CLOSE UP MEETING.SAYS 7 OBSERVATIONS ARE IMPROVEMENT IN PROCEDURES AND PRACTICES.SAYS 3 OBSERVATIONS RELATED TO SETTING OF ANALYTICAL SPECIFICATIONS, TEST PROCEDURES, METHOD VALIDATION.  Full Article

India's Shilpa Medicare Sept-qtr profit rises
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Shilpa Medicare Ltd ::Sept quarter profit 481.9 million rupees versus 331.9 million rupees year ago.Sept quarter revenue from operations 1.94 billion rupees versus 1.96 billion rupees year ago.  Full Article

India's Shilpa Medicare says Rajendra Dugar resigns as CFO
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Shilpa Medicare Ltd :Says Rajendra Dugar resigns as CFO.  Full Article

Shilpa Medicare Dec-qtr profit falls
Tuesday, 14 Feb 2017 

Shilpa Medicare Ltd : Dec quarter net profit 273.5 million rupees versus profit 321.3 million rupees year ago .Dec quarter total income 1.76 billion rupees versus 1.90 billion rupees year ago.  Full Article

Shilpa Medicare gets USFDA approval for capecitabine tablets USP
Tuesday, 13 Dec 2016 

Shilpa Medicare Ltd :Shilpa Medicare -got approval from USFDA for capecitabine tablets USP, 150 mg and 500 mg to be bioequivalent and therapeutically equivalent to reference listed drug product.  Full Article

Shilpa Medicare gets USFDA approval for Azacitidine injection
Tuesday, 4 Oct 2016 

Shilpa Medicare Ltd :Received an approval from the United States Food & Drug Administration for Azacitidine - Injection Anda of SEZ formulations facility situated at Jadcherla.  Full Article

Shilpa Medicare June-qtr profit rises
Friday, 26 Aug 2016 

Shilpa Medicare Ltd : June-quarter profit 241.4 million rupees versus 221.3 million rupees last year . June-quarter total income 1.61 billion rupees versus 1.46 billion rupees last year .  Full Article

Shilpa Medicare says USFDA conducted audit at Jadcherla facility
Tuesday, 26 Jul 2016 

Shilpa Medicare Ltd : Co had an audit conducted by USFDA at SEZ Formulations facility situated at Jadcherla, near Hyderabad, from July 18 to July 26 . Co has received no 483 observations for the facility .  Full Article

Shilpa Medicare to consider merger of Navya Boilogicals Pvt Ltd with co
Thursday, 23 Jun 2016 

Shilpa Medicare Ltd : To consider a proposal of merger of Navya Boilogicals Private Limited with the company .  Full Article

Shilpa Medicare approves acquisition of NU Therapeutics
Monday, 30 May 2016 

Shilpa Medicare Ltd : Approved acquisition of 100 percent shares of NU Therapeutics;deal to result in investment of up to INR 32.1 million in NU Therapeutics .  Full Article

BRIEF-Shilpa Medicare Gets 483 Observations From U.S. FDA For SEZ Formulation Facilities In Telangana

* SAYS GOT 483 OBSERVATIONS FROM U.S. FDA IN RELATION TO SEZ FORMULATION FACILITIES SITUATED AT JADCHERLA, TELANGANA